Press release

MIDO 2017: Evonik presents TROGAMID® for more freedom of design in optical applications

January 20, 2017

Evonik will be at this year’s MIDO in Milan, Italy, presenting an innovative technology for manufacturing eyeglasses frames: IMPLEX is based on TROGAMID®, a transparent, high-performance plastic, and gives eyewear manufacturers more freedom of design.

Unlike traditional production methods, this novel technology involves cutting the finished frames from a single, curved preform, thus omitting the machining and finishing steps after injection molding. The preform is made ahead of time from multiple functional layers—the base frame made of TROGAMID®, the adhesive and coating layers, or the scratch-resistant film—and can be produced relatively quickly and flexibly, varying both the size of the preform and its radius of curvature.

Design variety with TROGAMID®
IMPLEX wins customers over with easy handling, excellent productivity, and the ability to customize in a variety of colors, textures, and patterns. For eyewear manufacturers, the ability to implement designs even more quickly is a major advantage of the innovative technology.

The innovation meets customer demands through its use of two material solutions from Evonik: TROGAMID® CX9704 is a transparent polyamide used for the base frame—its pliability allows manufacturers to vary the shape of the product. The second structural layer, which is made with TROGAMID® CX9711, has excellent processing characteristics and is highly resistant to chemicals.

Cooperation between Evonik and Tungfung
The development of IMPLEX is based on decades of materials experience that Evonik has amassed in the field of high-performance plastics, along with technical expertise in the optics industry provided by Tungfung, a professional eyewear producer headquartered in Hong Kong. Evonik offers the right material and product expertise, while Tungfung serves as an expert partner in the production of exceptional eyeglasses frames.

Caption: IMPLEX preform based on TROGAMID®.

Caption: IMPLEX preform based on TROGAMID®.

Caption: The IMPLEX preform is made ahead of time from multiple functional layers.

Caption: The IMPLEX preform is made ahead of time from multiple functional layers.

Learn more about high-performance plastic TROGAMID® for optical applications at our booth (G61, Hall 2) at MIDO, February 25 – 27, in Milan, Italy.

Contact

Scarlett Shi

Contact

  • Company information

    Evonik, the creative industrial group from Germany, is one of the world leaders
    in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

  • Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late 1970’s; with wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavor to grow our business in the region. The company now has around 3,000 employees in the Greater China region, the regional sales reached over €1.3 billion in 2015.

  • Disclaimer

    In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.